Mucoless

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mucoless

Property Description
Active ingredient Bromhexine hydrochloride
Form Tablet, Oral solution (Syrup), Injectable solution
Pharmacological class Mucolytic, Secretolytic, Expectorant agent
Common use Facilitating the clearance of thick mucus
Origin Synthetic compound (derived from vasicine)

Mucoless is a pharmaceutical preparation containing the sole active ingredient, Bromhexine hydrochloride (INN), which is classified as a mucolytic and secretolytic agent within the respiratory system therapeutics group. This medicine is designed specifically to reduce the viscosity of respiratory secretions. Bromhexine is a clinically recognized mucolytic agent used for conditions involving increased mucus secretion, aiding in clearance and improving breathing.

Bromhexine: Composition, Origin, and Forms

The active substance in Mucoless is Bromhexine, which is a synthetic compound derived chemically from the plant alkaloid vasicine. The final product contains Bromhexine hydrochloride, formulated into various dosage forms, including the standard tablet for oral administration and the oral solution (syrup), often preferred for pediatric patients or those with swallowing difficulties. The preparation is consistently manufactured as a single-ingredient product, ensuring that its entire action is focused on its mucolytic properties.

General Purpose and Mechanism of Action

The general purpose of Mucoless is to facilitate the efficient evacuation of thick, retained mucus from the lungs and airways, supporting easier breathing. It achieves this by directly initiating a change in the physical properties of the secretions. The core benefit stems from its targeted action: it works by promoting the hydrolytic depolymerization of mucopolysaccharide fibers in the sputum, transforming sticky secretions into a more fluid state. This action is critical for supporting the natural mechanisms of ciliary clearance of the respiratory tract. Mucoless fundamentally addresses the consistency of the mucus to ensure the body can expel it more effectively.

What side effects are possible with Mucoless?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Mucoless (Bromhexine hydrochloride) as officially documented in government regulatory sources.

Adverse effects are classified according to frequency, with most effects being officially categorized as Rare or Not Known (frequency cannot be estimated from available data) in regulatory documents.

Documented Adverse Reactions

The most frequently reported adverse reactions, classified as Rare in official labeling, include gastrointestinal effects such as nausea, vomiting, diarrhoea, and epigastric pain. Skin reactions such as rash and urticaria are also listed as Rare.

More serious, yet less common, reactions that have been documented are classified under Not Known frequency. These include severe allergic manifestations like anaphylactic reactions (including anaphylactic shock) and angioedema, as well as life-threatening skin disorders known as Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These effects relate to the Immune system and the Skin and subcutaneous tissue system-organ classes.

Safety Considerations for Specific Populations

Official labeling contains specific safety statements concerning certain patient groups. Caution is advised for individuals with severe hepatic or renal impairment, as drug clearance may be reduced. Use requires caution in patients with a history of gastric ulceration and in patients susceptible to bronchospasm (e.g., those with bronchial asthma).

Furthermore, the medicine is not recommended for use during the first trimester of pregnancy or for nursing mothers, as excretion into breast milk is documented and not fully quantified.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Mucoless (Bromhexine hydrochloride) confirms that no unique clinical syndrome of overdosage has been specifically documented in man. Manifestations observed following accidental or intentional overdose are generally consistent with the compound's known adverse effects.

Overdose Presentation Regulator-Mandated Action
Documented Signs: Symptoms may involve the gastrointestinal system, including nausea, vomiting, diarrhoea, and upper abdominal pain. Systemic effects such as headache and dizziness may also occur. Seek Urgent Medical Help: Immediate medical attention must be sought in cases of suspected overdose. Contact a doctor, pharmacist, or the national Poisons Information Centre.
Severe Outcomes: Regulators highlight the risk of severe reactions such as anaphylactic shock, angioedema, and severe cutaneous adverse reactions (SCARs). Immediate Cessation: If new skin or mucosal lesions, or signs of severe allergy (e.g., difficulty breathing, swelling), appear, stop treatment immediately and contact emergency services without delay.

Management of overdosage is strictly symptomatic treatment and general supportive care as indicated by the patient's condition, since no specific antidote is available. The primary requirement for immediate medical help is based on suspected ingestion beyond recommended limits or the onset of severe, potentially life-threatening reactions cited in the official risk statements.

Therapeutic Uses of Mucoless

What Mucoless Treats: Main Uses and Benefits

The medicine is commonly used for managing symptoms related to chest congestion and cough, which are commonly observed in conditions characterized by periods of heightened symptoms. It is relevant for easing symptoms that interfere with daily functioning in the respiratory tract. Mucoless helps address symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort in the chest and airways.


Relieving Acute Respiratory Discomfort

This medicine is commonly used in clinical settings that involve acute or unstable symptom patterns, applying during phases when symptoms become more noticeable. Mucoless helps address symptoms related to heightened physiological activity in the airways, contributing to improved comfort during periods of intensified respiratory strain. It is used across domains where additional symptomatic support is needed.


Supporting Symptom Management

The medicine is applied across domains where additional symptomatic support is needed, particularly in situations involving recurrent or episodic manifestations. It provides support that helps ease the overall symptom burden when symptoms lead to temporary functional strain or discomfort.

Quick Fact: Managing Symptoms of Stuffy Breathing


Patient-Oriented Benefit

Mucoless is relevant for easing symptoms linked to organ-specific functional stress. It assists with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods, supporting patients during episodes of heightened discomfort.

Eligibility and Restrictions for Use

Who Can and Cannot Use Mucoless?

This section outlines population eligibility rules for Mucoless (Bromhexine), based strictly on official regulatory documents concerning contraindications and restrictions.

Absolute Contraindications

Mucoless must not be used by patients with a known hypersensitivity (allergy) to bromhexine or any component of the formulation. Use is generally contraindicated or labeled with "Do not use" for children under 6 years of age in many regulatory regions. Furthermore, patients with rare hereditary conditions like fructose intolerance are prohibited from using certain excipient-containing formulations.

Age-Based and Conditional Use

Use is approved for adults and children aged 12 years and over. For children aged 6 to 11 years, use is permitted but often requires the advice of a health professional.

The medicine must be used with caution in patients with a history of peptic or gastric ulceration. Caution is also required for patients suffering from severe hepatic impairment (liver disease) or severe renal impairment (kidney disease), as the elimination of metabolites may be reduced.

Pregnancy and Lactation Status

Use is not recommended and preferable to avoid during pregnancy, especially the first trimester, due to limited human data. Mucoless should not be used during breast-feeding due to the potential risk to the infant, as metabolites are excreted in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Mucoless (Bromhexine hydrochloride) as defined in government regulatory documents.

Component Official Regulatory Statement
Medicinal product categories with documented interactions Antitussives, Secretion-drying medications, and specific Antibiotics.
Specific interacting medicines (if explicitly listed) Amoxycillin, Erythromycin, Oxytetracycline.
Interaction-related restrictions Must not be administered concomitantly with antitussives or secretion-drying medications.
Population-specific interaction notes (if applicable) Clearance of Bromhexine or its metabolites may be reduced in patients with severe hepatic impairment or severe renal failure.

Resulting Interaction Structure

Official regulatory information restricts the co-administration of Mucoless with substances classified as antitussives or secretion-drying medications. This is a formal, prohibitive restriction based on an opposing pharmacodynamic effect that could lead to the accumulation of secretions.

A documented pharmacodynamic effect is the increased concentration of the antibiotics amoxycillin, erythromycin, and oxytetracycline in sputum and bronchopulmonary secretions following co-administration.

Regarding pharmacokinetic modification, concomitant food intake is documented to result in an increase of bromhexine plasma concentrations. Furthermore, the regulatory profile includes a population-specific pharmacokinetic consideration that clearance of Bromhexine or its metabolites may be reduced in patients with severe hepatic or renal impairment.

Mechanism of Action

How Mucoless Works: Mechanism of Action

Mucoless is a mucoactive agent that influences the respiratory system by modulating both the physicochemical properties of airway secretions and the mechanisms governing their transport. Its action is defined by two primary mechanistic domains: the direct biochemical modification of mucus and the modulation of the mucociliary system.


Disulfide Bond Hydrolysis

Mucoless functions as a reducing agent that targets the disulfide bonds linking polymeric mucin proteins. This process initiates the fragmentation of the high-molecular-weight, cross-linked mucin network, leading directly to a reduction in the viscosity and elasticity of the airway fluid. This structural change diminishes intermolecular adhesion and alters the rheological profile of the secretion.


Secretomotor and Ciliary Pathway Modulation

The drug engages mechanisms that stimulate serous gland activity, which in turn increases the relative volume of fluid with low kinematic viscosity. This secretion acts to dilute the overall concentration of mucins. Concurrently, Mucoless influences ciliary function, supporting the maintenance of ciliary beat frequency and coordination. The combined effect on fluid volume and ciliary movement alters the physical boundary conditions necessary for the transport mechanism.

Dosage and Administration Information

How to Use Mucoless

The usage of Mucoless (bromhexine hydrochloride) follows established parameters that specify the administration routes, dosing frequency, and duration of use. This information is based on standardized guidelines to ensure consistency in administration.


Official Administration Guidelines

Property Administration Rule
Route of Administration Primarily Oral for tablets and liquid forms. An Intravenous injectable solution exists in certain global markets.
Dosing Frequency Typically administered three times a day (t.i.d.). Some regimens allow for up to four administrations daily for short periods.
Timing in Relation to Meals The medicine can be taken with or without food.
Duration of Course Treatment is generally intended for short-term use and should not exceed seven consecutive days without medical re-evaluation.

Labeled Dosing and Special Instructions

Administration schedules define the exact quantity of the active substance to be taken. The standard adult dose ranges from 8 mg per dose up to 16 mg per dose. A higher dose may be used during the first seven days of treatment before reducing to a maintenance level.

Population-Specific Dosing

Standard labels detail modified regimens for children. For instance, children aged 6 to 12 years are typically administered 8 mg per dose, while children 2 to 5 years receive lower doses, such as 4 mg per dose. Furthermore, the 8 mg tablet and higher-strength liquid forms are generally not recommended for use in children under 6 years of age. For liquid forms, administration requires the use of the provided measuring device to ensure dose accuracy.

Recent Clinical Evidence

Research evidence / Overview of studies for Mucoless

Evidence for Secretolytic Therapy in Respiratory Conditions

The research for Mucoless was conducted in settings where patients experience conditions characterized by heightened symptom activity related to thickened mucus. This includes both chronic conditions, such as chronic bronchitis, and acute respiratory tract infections. Clinical research for this medicine was studied for its role in exploring changes in the characteristics of respiratory secretions. The study designs used in research exploring how symptoms change over time include short-term Randomized Controlled Trials (RCTs), as well as systematic reviews that synthesize findings from multiple sources.

These studies monitored outcomes related to physical discomfort. Researchers examined changes in the physical properties of the mucus, such as its viscosity and volume, and also tracked patient-reported outcomes describing perceived discomfort. Studies reported patterns of measurable changes in mucus stickiness. Other research described differences in patient-reported experiences between the medicine and placebo groups.

Studies Examining Symptom and Mucus Changes

This subsection focuses on the specific measures applied in studies examining patient-reported experiences related to episodic or acute changes. The studies explored what happens to the mucus itself. Specifically, trials monitored changes in the physical characteristics of sputum and sometimes monitored measures related to mucociliary clearance. Research describes that when used during periods of increased symptom activity, changes were observed in some studies regarding patient-reported experiences with expectoration. This evidence contributes to understanding symptom patterns and provides insight into short-term changes in outcomes related to physical discomfort.

Long-Term Evidence and Observation Durations

The majority of the research conducted on Mucoless was applied in studies examining patient-reported experiences relevant in trials assessing short-term or episodic symptom patterns. Follow-up durations were limited to short time intervals, typically lasting a few days to a few weeks. Limited information is available for long-term outcomes, and the effects of continuous use over extended periods may not be fully understood. Long-term effects are not fully established; studies help show what has been observed so far, but limited data are available for extended-duration effects.

Areas of Uncertainty and Research Gaps

The existing research contributes to the broader evidence landscape, but it details the available evidence and areas remaining uncertain. Evidence quality varies across studies, with some clinical trial results being described as having low consistency or showing mixed findings. The study sizes were small in many trials, which can limit the certainty of the findings. Research is ongoing, but there is still a need for further large-scale, methodologically robust studies to achieve greater clarity and consistency.

Frequently Asked Questions (FAQ)

Common questions about Mucoless (FAQ)


Q: Are there any long-term side effects associated with Mucoless use?

Studies examining this medicine were typically short-term, lasting a few days to a few weeks. Official information states that limited data is available regarding long-term outcomes. Because of this, the effects of continuous use over extended periods may not be fully established.


Q: Is it true that Mucoless is not effective for everyone?

The clinical research supporting the use of Mucoless has sometimes shown variability in results. Official documents have described findings as having low consistency or showing mixed results across different studies. This contributes to the general understanding that individual responses to the medicine may vary.


Q: Is Mucoless the same as other 'mucus' relief medicines I see advertised?

Mucoless is officially classified as a mucoactive agent, specifically a mucolytic. The medicine is defined by its action to directly influence the structure of the mucus by reducing its viscosity and elasticity. This action differs from some other over-the-counter medicines that may focus only on encouraging the body to cough up secretions.


Q: What if Mucoless doesn't seem to be working after a few days?

Official usage guidelines specify that Mucoless is intended for short-term use. Treatment should generally not exceed seven consecutive days. If this timeframe is reached and the medicine does not appear to be working, regulatory guidance mentions the need for medical re-evaluation.


Q: Does Mucoless contain any common allergens like gluten or lactose?

The full list of excipients (inactive ingredients) is detailed in the official product information. Regulatory labeling includes a prohibition against use for patients with rare hereditary conditions, such as fructose intolerance, due to the presence of specific excipients in some formulations. Reviewing the official ingredient list is a method used to check for specific allergies or intolerances.


Q: Does Mucoless help with thick phlegm?

Yes, the primary purpose of Mucoless is to facilitate the efficient evacuation of thick, retained mucus from the lungs and airways. Phlegm is a common term used to describe this thick respiratory mucus. It works by reducing the stickiness and elasticity of the secretions.


Q: How long do the effects of one dose of Mucoless last?

The official dosing schedules typically suggest the medicine be administered three times a day. Scientific documents report that the terminal elimination half-life of the active ingredient ranges between 6.6 and 31.4 hours. This half-life is the measure of how long it takes for the amount of medicine in the body to reduce by half.


Q: What kind of research has been done on Mucoless?

Clinical research has primarily included short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies have focused on examining changes in the physical properties of respiratory secretions, such as viscosity, and patient-reported discomfort. The findings contribute to understanding symptom patterns over short time intervals.


Q: Is Mucoless a controlled substance?

Regulatory-adjacent patient safety information reports the active ingredient as having no habit-forming tendencies. This fact can be used to describe the regulatory scheduling or classification of the drug.


Q: Does Mucoless require a prescription?

The regulatory status of products containing this active ingredient varies depending on the specific country and formulation. Official information states that the majority of products are available over the counter, while some may be prescription-only.


Q: Can Mucoless make you feel dizzy or lightheaded?

Official documents list dizziness as a documented adverse reaction to the medicine. The frequency of this effect is often classified as Not Known, meaning it cannot be reliably estimated from the available data.


Q: Does Mucoless cause stomach upset?

Yes, gastrointestinal issues are listed among the documented side effects. Adverse reactions such as nausea, vomiting, diarrhoea, and epigastric pain (upper abdominal pain) are listed, generally classified as Rare or Uncommon in frequency.


Q: Are there known interactions between Mucoless and alcohol?

The official interaction sections primarily focus on other medicines and products like food. Some official-adjacent patient safety advice indicates that the specific interaction between this medicine and alcohol is unknown.


Q: What kind of warnings are associated with overdose of Mucoless?

Regulatory documents state that specific overdose symptoms have not been reported in human cases. Instead, the observed symptoms were consistent with the known side effects that occur at recommended doses.


Q: Does Mucoless affect the ability to drive or operate machinery?

Official labeling states that when the medicine is used as recommended and in the absence of side effects, it is not known to have any effect on the ability to drive or operate machinery. However, potential impairment may be possible in cases where adverse reactions, such as dizziness, occur.


Q: Does Mucoless have a sedative effect?

Sedative effects or general sleepiness are not listed as an adverse reaction in official regulatory documents. Some patient information sources explicitly state the medicine is not known to cause sleepiness.

How should Mucoless be stored and disposed of?

Storage and Disposal Conditions for Mucoless

Official Storage Requirements

Mucoless oral solution must be stored in a dark and dry place at a temperature below 25°C.

Storage Classification Requirement
Temperature Store below 25°C
Environment Dark and dry place

For stability, the product should not be used after its printed expiry date. Once the bottle has been opened, the solution must be used within 4 months; this 4-month period cannot extend beyond the final expiry date on the packaging.

Protection and Disposal

This medicine must be stored in a secure location out of the sight and reach of children and infants to prevent accidental ingestion.

Specific instructions for the disposal of Mucoless are typically not provided on the product label. Unused or expired medication should be disposed of using established methods, such as a Drug Take-Back Program or following official guidance for proper household trash disposal, which involves mixing the medicine with an unappealing substance and sealing it in a container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mucoless found in:

A-Z Index: